

[Nevirapine](#)

Essential medicine status

Section:

[6. Anti-infective medicines](#) [6.4. Antiviral medicines](#) [6.4.2. Antiretrovirals](#) [6.4.2.2. Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors](#)

ATC codes: [J05AG01](#)

EMLc

Indication

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

ICD11 code: [1C62.Z](#)

INN

Nevirapine

Medicine type

Chemical agent

List type

Core

Formulations

Oral > Liquid: 50 mg per 5 mL

Oral > Solid > dispersible tablet: 50 mg

Oral > Solid > tablet: 200 mg (EML)

EML status history

First added in 1999 ([TRS 895](#))

Changed in 2002 ([TRS 914](#))

Changed in 2007 ([TRS 950](#))

Changed in 2015 ([TRS 994](#))

Changed in 2023 ([TRS 1049](#))

Sex

All

Age

Also recommended for children

Age restriction

> 6 weeks

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Nevirapine](#)

DrugBank

[Nevirapine](#)

Summary of evidence and Expert Committee recommendations

The Expert Committee recommended addition of nevirapine 50 mg dispersible tablet formulation to the core list of the EML and EMLc for the treatment of children and adolescents with HIV-1 infection. The Expert Committee agreed on the public health need for paediatric formulations of ART medicines and considered that the proposed formulation of nevirapine represented a rational treatment option for paediatric HIV patients. The Committee noted that this formulation is included in the 2013 WHO guidelines and are categorized by the IATT as an “optimal” paediatric formulation.